Abcuro Announces Participation in Upcoming Investor Conferences

NEWTON, Mass.--(BUSINESS WIRE)-- Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences.

• Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm E.T.
• Piper Sandler 36th Annual Healthcare Conference: Presentation on December 3, 2024, at 4:10 pm E.T.

About Abcuro

Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The company’s lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.

For more information, visit us on LinkedIn and at abcuro.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241111552514/en/

Matthew DeYoung
Investor Relations and Media
Argot Partners
[email protected]

Source: Abcuro, Inc.

You May Also Be Interested In

• Faraday Future Announced that It has Entered Into Incremental Warrant Termination Agreements With Each March 2025 Financing Investor as It Continues to Make Progress in Reducing Its Debt and Improving
• JBL Launches JBL Cove: A New Whole-Home Audio System to Enjoy Superior Sound Throughout the Entire Home
• KBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-5 (AOMT 2026-5)